We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
-9.52%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$985M
AUM Growth
-$142M
Cap. Flow
+$49.9M
Cap. Flow %
5.07%
Top 10 Hldgs %
58.04%
Holding
76
New
11
Increased
24
Reduced
21
Closed
19

Top Buys

Rank Stock Value
1
SNDX icon
Syndax Pharmaceuticals
SNDX
+$54.6M
2
PCVX icon
Vaxcyte
PCVX
+$34.3M
3
GKOS icon
Glaukos
GKOS
+$21.2M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$21.2M
5
CYH icon
Community Health Systems
CYH
+$17.5M

Top Sells

Rank Stock Value
1
GSK icon
GSK
GSK
+$38M
2
INSP icon
Inspire Medical Systems
INSP
+$19.5M
3
VTRS icon
Viatris
VTRS
+$15.8M
4
TEVA icon
Teva Pharmaceuticals
TEVA
+$14.9M
5
EW icon
Edwards Lifesciences
EW
+$12.6M

Sector Composition

Rank Sector Weight
1 Healthcare 88.54%
2 Miscellaneous 11.4%
3 Financials 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PDCO
76
DELISTED
Patterson Companies, Inc.
PDCO
– –
-146,051
Closed -$4.51M
1 2 3
4

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q1 2025 Portfolio in Review

As of Q1 2025, Eversept Partners held 76 positions worth $985M, down 13% from $1.13B the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Eversept Partners deployed $49.9M of net new capital in Q1 2025, opening 11 new positions and adding to 24 existing holdings. Its largest new stake was Glaukos: 158,957 shares worth $15.6M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 86% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was GSK, an estimated $38M trimmed.

  • Eversept Partners's largest Q1 2025 buy was Glaukos: 158,957 shares worth $15.6M.
  • Eversept Partners added most to Syndax Pharmaceuticals in Q1 2025, an estimated $54.6M increase.
  • Eversept Partners's biggest Q1 2025 reduction was GSK, cutting an estimated $38M.
  • Eversept Partners fully exited Viatris in Q1 2025, selling an estimated $15.8M.
  • Eversept Partners's ten largest holdings make up 58% of its $985M portfolio in Q1 2025.
  • Eversept Partners opened 11 new positions and closed 19 in Q1 2025.
  • Eversept Partners's portfolio value fell 13% quarter-over-quarter to $985M.

Based on Eversept Partners's 13F filing for Q1 2025, filed 15 May 2025.